Thomas G. Martin, MD
Emerging treatments continue to shift the paradigm in multiple myeloma, including those designed to improve the quality of life for these patients.
on Hematologic Malignancies, Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director of the Myeloma Program, co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discussed emerging advancements in the treatment landscape of multiple myeloma.
OncLive®: Can you discuss the recent FDA approval of denosumab?
: I am excited that denosumab has just received FDA approval for the treatment of patients with plasma cell disorders. Bone disease is a significant complication in multiple myeloma. We had several bisphosphonates, [specifically] pamidronate and zoledronic acid, that have proved efficacious in multiple myeloma, and now there is a third agent.
... to read the full story